| EPC009 | Change in body weight after substituting efavirenz for dolutegravir in adults living with HIV in Johannesburg, South Africa | E-poster | Epidemiology of HIV in the general population |
| EPC008 | New challenges to reduce HIV mortality in Mexico: epidemiological trends have changed | E-poster | Epidemiology of HIV in the general population |
| EPC006 | Causes of death for persons with HIV in an integrated healthcare system in Northern California, 2013-2017 | E-poster | Natural history, morbidity patterns and survival |
| EPC005 | Most common causes of death among persons living with HIV ' Zambia, February 2020-January 2022 | E-poster | Natural history, morbidity patterns and survival |
| EPC004 | Geographic variation in 5-year mortality following HIV diagnosis: implications for clinical interventions | E-poster | Natural history, morbidity patterns and survival |
| EPC003 | Survival and determinants of mortality among HIV infected persons in rural Malawi: a historical cohort study of before test and treat strategy | E-poster | Natural history, morbidity patterns and survival |
| EPC002 | Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study | E-poster | Natural history, morbidity patterns and survival |
| EPB271 | Decay pattern of anti'SARS-CoV-2 antibodies in people with HIV | E-poster | Clinical manifestations and features of COVID-19 and HIV co-infection |
| EPB270 | Body composition and SARS-CoV-2 antibody levels among underserved populations in Miami, Florida: a rapid acceleration of diagnostics-underserved populations (RADxUP) study | E-poster | Clinical manifestations and features of COVID-19 and HIV co-infection |
| EPB269 | Humoral immune response to COVID-19 vaccination in HIV infected adults with and without prior COVID: comparison with HIV uninfected controls | E-poster | Clinical manifestations and features of COVID-19 and HIV co-infection |